Marea reports early Phase 2 data for cholesterol-lowering drug it licensed...
Marea Therapeutics on Friday posted some encouraging results with its lead program, a triglyceride-lowering medicine for cardiovascular disease, that could give an indication of whether the investors...
View ArticleRepare pauses late-stage plans, reshuffles pipeline in effort to cut costs
Repare Therapeutics is slamming the brakes on its gynecologic cancer assets and prioritizing earlier-stage candidates as part of a series of changes designed to stretch its cash reserves. The biotech is
View ArticleLilly ventures into pulmonary fibrosis with startup Mediar
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay $99 million in...
View ArticleJohn Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet;...
→ City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John Maraganore to run it back with RNAi-based therapies. This week, the company ...
View ArticleAnother biotech scoops up asset from China-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets discovered or initially...
View ArticleCDER Director Patrizia Cavazzoni to step down
Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, will step down, the agency confirmed Friday. An email was sent to employees announcing the departure. "Leaving CDER...
View ArticleFour biotechs emerge with $800M and in-licensed assets on Friday
Four new biotechs launched Friday with megarounds and in-licensed treatment candidates, giving the industry an $800 million boost ahead of the year's biggest dealmaking event in San Francisco. Three of...
View ArticleCity Therapeutics, Bausch + Lomb partner on preclinical RNAi eye drug
With its new CEO installed this week, City Therapeutics is aiming to capitalize on the momentum in signing a new deal. The startup is partnering with Bausch + Lomb on an experimental ...
View ArticleStemson Therapeutics shutters; Insilico teams up again with Menarini
Plus, news about Crinetics, Compass Pathways, Amylyx Pharmaceuticals, Mersana Therapeutics, Guggenheim Partners, Sciwind Biosciences, 4D Molecular Therapeutics, Barinthus Bio, Y-mAbs Therapeutics and...
View ArticleEndpoints at JPM 2025: China, Trump 2.0, markets and more
When we started putting together this year’s JPM agenda, we had three major focus areas: The transition to Trump 2.0; the on-again, off-again market recovery, and the evolving US-China dynamic. These...
View ArticleModerna's former top scientist Moore has a new mRNA startup
Melissa Moore helped usher in the first mRNA medicines, but the former Moderna executive thinks there’s still a lot of room for improvement. The rapid success of the first mRNA vaccines during the...
View ArticleAbbVie writes off $3.5B on Cerevel drug after Phase 2 failures
AbbVie is taking a major loss in the wake of its Cerevel buyout. AbbVie said it will write off $3.5 billion following two mid-stage failures for emraclidine, the experimental schizophrenia drug that...
View ArticleDyne details pivotal plans for myotonic dystrophy RNA drug, though data blip...
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it plans to move forward into pivotal studies. However, the company’s shares...
View ArticleLilly finances new $500M biotech fund managed by a16z
Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new $500 million biotech fund. The pharma company is providing all the capital for...
View ArticlePfizer touts bladder cancer results as first advancement for some patients...
Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where progress has been limited. Its therapy, called sasanlimab, significantly prolonged...
View ArticleLawmakers ask administration to tighten China trial rules
Members of Congress working on anti-China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites operated by the People’s Liberation Army....
View ArticleFDA adcomm votes to support Seikagaku's herniated disc injection
Despite some safety concerns, an FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment of radicular leg pain associated with lumbar...
View ArticleObesity drug startup Metsera files for IPO
Metsera has filed to go public less than a year after its launch, capitalizing on the fervent investor interest — and intense competition — for all things obesity. The startup's sprint toward an IPO...
View ArticleBiogen offers to buy Sage Therapeutics for $469M
Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slide...
View ArticleDNA edit leads to apparent cure in infant; CDER director to step down; More...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View Article